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Body mass index does not impact on molecular response rate
of chronic myeloid leukaemia patients treated frontline with
second generation tyrosine kinase inhibitors
Excessive body weight, typically considered as a body mass
index (BMI) greater than 25 kg/m2 of body surface area
according to the World Health Organization classification
(Finucane et al, 2011), has been associated with a higher risk
of cancer development, including breast cancer in women
and esophageal, colon, pancreatic, endometrial and kidney
cancers in both genders (Bianchini et al, 2002). Obesity has
also been correlated with the onset of haematological malig-
nancies (Soderberg et al, 2009). The relative risk of develop-
ing leukaemia has been reported to be 114 for overweight
(BMI 25- < 30 kg/m2) and 139 for obese (BMI ≥30 kg/m2)
individuals (Larsson & Wolk, 2008). Research from the MD
Anderson Cancer Center has suggested that obesity and
adulthood weight gain may increase the risk of developing
chronic myeloid leukaemia (CML) (Strom et al, 2009). In
2012, our group reported that CML patients with an
increased BMI (>25 kg/m2) at diagnosis who received ima-
tinib showed a significantly longer median time to obtain a
complete cytogenetic response (CCyR, 68 months vs.
33 months, P = 0001) and a reduced rate of major molecu-
lar response (MMR, 77% vs. 58% P = 001), which was also
achieved over a longer median time (29 months vs
14 months, P = 001) compared to patients with a lower
BMI (Breccia et al, 2012). We suggested that having a higher
BMI at diagnosis might be considered a risk factor in terms
of response achievement and time of response to treatment
in CML patients treated with imatinib frontline. The present
study was designed to assess the rate of response in a cohort
of chronic phase CML patients treated upfront with second-
generation tyrosine kinase inhibitors (TKIs) according to
BMI at diagnosis. Seventy-eight patients diagnosed between
May 2007 and October 2016 at our centre - 53 treated with
nilotinib and 25 with dasatinib - entered this analysis. BMI
was defined as the body mass divided by the square of the
body height, universally expressed in kg/m2. According to
the BMI, patients were classified into 4 subsets: underweight
(<185), normal weight (>185–<25), overweight (>25–<30)
and obese (>30). In our cohort, 40 patients (513%) were
categorized as underweight/normal weight, while 38 (487%)
were classified as overweight/obese. Median age at diagnosis
was 56 and 55 years for the two subsets of patients, respec-
tively (P = not significant). A correlation was identified
between increased BMI and gender, with a higher percentage
of males being overweight/obese compared to females (68%
vs. 42%, P = 001). We found no statistically significant asso-
ciation between BMI and prognostic risk stratifications at
diagnosis [European Treatment and Outcome Study
(EUTOS), Sokal, Hasford and EUTOS long-term survival
scores]. Two patients died of CML progression after having
developed an ABL1 T315I mutation, both belonging to the
underweight/normal weight group (Table I). All patients
were followed according to the 2013 European LeukaemiaNet
(ELN) recommendations (Baccarani et al, 2013). We assessed
the cytogenetic and molecular responses at 3 months and at
Table I. Clinical and biological features at baseline according to
BMI.
BMI <185 185-<25 >25-30 >30 P-value
Patients, n 1 39 30 8
Median age (years) 373 56 55 47 ns
Gender
Male / 16 21 5 001
Female 1 23 9 3
Sokal score
Low 1 18 17 6 ns
Intermediate / 17 10 1
High / 4 3 1
EUTOS score
Low 1 34 29 7 ns
High / 5 1 1
Hasford score
Low 1 21 19 4 ns
Intermediate / 17 8 3
High / 1 3 1
EUTOS long-term survival score
Low 1 27 27 6 ns
Intermediate / 10 2 2
High / 2 1 /
Type of transcript
b2a2 / 9 10 3 ns
b3a2 1 30 16 5
b2a2 and b3a2 / / 4 /
Type of second generation TKI
Nilotinib / 24 22 7
Dasatinib 1 15 8 1
Death for CML / 2 / /
BMI, body mass index; CML, chronic myeloid leukaemia; EUTOS,
European Treatment and Outcome Study; ns, not significant; TKI,
tyrosine kinase inhibitor.
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12 months, and the best molecular response achieved com-
paring the underweight/normal weight group and the over-
weight/obese group. At 3 months, there were no significant
differences in CCyR rate between patients with lower BMI
(<25) and higher BMI (>25) (975% vs. 100%; P = 032).
Early molecular response (EMR or a BCR-ABL1/ABL1 ratio
≤10% at 3 months), MMR (BCR-ABL1/ABL ratio ≤01%)
and deep molecular response (DMR, corresponding to MR4
or MR45) rates, were not statistically different when com-
paring the two subsets of patients (Table II). According to
the ELN 2013 guidelines, an optimal response was achieved
in 925% of patients with a lower BMI (<25 kg/m2) and in
947% of patients with a BMI higher than 25 kg/m2
(P = 068), while a warning response was seen in 75% and
53% of patients, respectively (P = 056). The results were
similar at 12 months of treatment for MMR (757% vs.
853%, P = 032) and DMR (454% vs. 50%, P = 050), but
were always non-significant between the two groups
(Table II). According to the ELN 2013 guidelines, 61% of
underweight/normal weight and 29% of overweight/obese
patients were considered as failures to second-generation TKI
treatment (P = 032). Finally, we assessed the cumulative
incidence of molecular responses achieved after a median fol-
low-up of 40 months. Again, no differences were found in
terms of MMR rate (35% vs. 289% P = 056), MR40
(225% vs. 289%, P = 051), MR45 rate (30% vs. 237%,
P = 062) for underweight/normal weight and overweight/
obese patients, respectively (Table II). Two patients achieved
a MR 50 (BCR-ABL1/ABL1 ratio ≤0001%) as their best
molecular response during the treatment, both belonging to
the overweight/obese group.
To our knowledge, this is the first analysis that considers
the prognostic impact of BMI on treatment response in
CML patients who received second-generation TKIs as
frontline therapy. It has been previously hypothesized that
imatinib, through the inhibition of PDGFRA and PDGFRB,
may alter the normal signalling regulation of macrophages
on pre-adipocytes stimulating adipogenesis (Yarmo et al,
2007) and that this interaction might explain the delayed
and low rate of molecular responses observed with this
drug as frontline treatment. On the contrary, we did not
find any significant difference in molecular response
between patients with low (<25) and high (>25) BMI who
received nilotinib or dasatinib as frontline treatment. The
high selectivity and potency of nilotinib and dasatinib (Jab-
bour, 2016) against BCR/ABL1 and the lower inhibition of
PDGFRA and PDGFRB, with a consequent lower adiponec-
tin differentiation, may explain the similar response rates
observed in underweight/normal weight and overweight/
obese patients to second generation TKIs. Our results sug-
gest that assessment of BMI at baseline should be consid-
ered as a decision factor prior to starting treatment in
CML patients. In the era of treatment-free remission as a
primary endpoint, imatinib seems contraindicated in obese
patients that need to reach early and deep molecular
responses. Indeed, obesity seems an initial risk factor coun-
terbalanced by the use of second generation TKIs, even if
cardiovascular risk and other comorbidities should be taken
into account in this subset of patients. Further validation of
the prognostic value of BMI on large series of patients trea-
ted frontline with all available TKIs is needed to confirm
its definitive role.
Table II. Cumulative incidences of responses according to BMI.
BMI <185–25 BMI >25– >30 P-value
CCyR rate (%) at 3 months 975 100 032
EMR rate (%) at 3 months 924 947 068
MMR rate (%) at 3 months 525 421 035
Response rate (%) according to ELN (2013)* at 3 months
Optimal 925 947 068
Warning 75 53
Failure / /
MMR rate (%) at 12 months 757 853 032
Response rate (%) according to ELN (2013)* at 12 months
Optimal 757 853 032
Warning 181 11.8
Failure 61 29
MMR rate (%) after median follow-up of 40 months 35 289 056
MR40† rate (%) after median follow-up of 40 months 225 289 051
MR 45‡ rate (%) after median follow-up of 40 months 30 237 062
BMI, body mass index; CCyR, complete cytogenetic response; DMR, deep molecular response; ELN, European LeukaemiaNet; EMR, early molec-
ular response; MMR, mayor molecular response; MR, molecular response.
*Baccarani et al (2013).
†MR 40 = BCR/ABL1 value ≤001%.
‡MR 45 = BCR/ABL1 value ≤00032%.
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